AbbVie Reports Will Present Results from Phase 2 PEARL-I Study in Genotype 4 Chronic Hep C Patients

By: via Benzinga
AbbVie (NYSE: ABBV) announced detailed results from its open-label Phase 2b study, PEARL-I, which demonstrated that 100 percent of ...
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.